APA (7th ed.) Citation

AG, H., MP, F., ME, B., C, J., PG, A., L, S., . . . J, T. (2018). Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 24(10), 2276. https://doi.org/10.1158/1078-0432.CCR-17-0646

Chicago Style (17th ed.) Citation

AG, Hill, et al. "Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) Versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 24, no. 10 (2018): 2276. https://doi.org/10.1158/1078-0432.CCR-17-0646.

MLA (9th ed.) Citation

AG, Hill, et al. "Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) Versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 24, no. 10, 2018, p. 2276, https://doi.org/10.1158/1078-0432.CCR-17-0646.